Matthew A. Powell, MD, Washington University in St. Louis

Articles

Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer

December 26th 2023

Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.

Unmet Needs in the Management of Patients With Advanced Endometrial Cancer

December 26th 2023

Looking ahead, Floor Backes, MD, notes that key needs in the treatment of advanced endometrial cancer are figuring out next steps when immunotherapy resistance develops, targeted radiation for oligometastatic disease, and sorting patients into subgroups for personalize care.

The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer

December 18th 2023

Floor Backes, MD, and Matthew Powell, MD, review data on sacituzumab govitecan, an antibody-drug conjugate targeting topoisomerase in patients with advanced endometrial cancer.

Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer

December 18th 2023

Drs Backes and Powell discuss the management of adverse events between upfront immunotherapy versus chemotherapy followed by later immunotherapy for endometrial cancer, noting the need for molecular subgroup data from trials like LEAP-001.

The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer

December 11th 2023

Matthew Powell, MD, and Floor Backes, MD, discuss real-world evidence from recent trials confirming benefit of immunotherapies in practice for patients with advanced endometrial cancer.

Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer

December 11th 2023

Drs Powell and Backes discuss additional immunotherapy trial results from ESMO 2023 including AtTEnd and DUO-E, noting differences across trials likely due to patient population composition rather than drug differences, and need for caution with PARP inhibitor maintenance.

Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial

December 4th 2023

Matthew Powell, MD, and Floor Backes, MD, enthusiastically discuss the practice-changing RUBY trial results presented at the 2023 ESMO Congress showing impressive survival benefits with immunotherapy plus chemotherapy for both MMR-deficient and MMR-proficient advanced endometrial cancer.

Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer

December 4th 2023

Experts review data on single-agent immunotherapy in patients with endometrial cancer from recent conferences, including ASCO 2023.

Key Takeaways From the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting

November 27th 2023

Drs Backes and Powell highlight key advances in endometrial cancer treatment from the 2023 SGO, ASCO, and ESMO conferences, including HER2-targeted therapies showing promising response rates.

Recent Advances in Endometrial Cancer

November 27th 2023

Matthew Powell, MD, and Floor Backes, MD, discuss recent advances in the molecular profiling and staging of endometrial cancer.